ISRG Q4 2024 Earnings Transcript

Intuitive Surgical reported 2024 revenue of $8.4 billion, up 17%, with da Vinci procedure growth also up 17% and pro forma EPS rising 28%-29% on strong adoption of da Vinci 5, Ion, and SP platforms. Q4 revenue grew 25% to $2.41 billion and pro forma operating margin reached 38%, but 2025 guidance calls for slower procedure growth of 13%-16% and lower margins of 67%-68% amid higher depreciation, mix pressure, tariffs risk, and competitive/capex headwinds in China and Europe. The company also announced a EUR290 million acquisition to expand direct presence in Southern Europe and highlighted strong clinical evidence supporting robotic outcomes.

Analysis

ISRG is entering a classic “good news, lower near-term margin” phase: the business is still compounding, but the next leg of growth is increasingly capital-intensive and mix-dilutive before it becomes accretive. The market is likely to over-focus on the guide-down in gross margin, but the more important signal is that utilization, procedure breadth, and international placements are all still rising simultaneously — that combination suggests the installed base is not saturating, just becoming more heterogeneous.

The second-order issue is that broad launch of DV5 may compress reported economics temporarily exactly when the company is trying to prove the platform’s superiority. Higher lease penetration, trade-in credits, and new factory depreciation can make 2025 look like a margin reset even if unit economics are improving underneath. That creates a setup where the stock can de-rate on accounting optics even while the franchise strengthens operationally, especially if investors model DV5 as a straight replacement cycle instead of a staged, progressive adoption curve.

The most underappreciated risk is not demand, but capital allocation friction: tariffs, geopolitics, and regional budget pressure can delay system placements and shift mix toward financing rather than purchase. That matters because it pushes revenue recognition out, raises perceived volatility, and could temporarily mask the inflection in recurring pull-through from procedure growth. On the upside, if DV5 adoption accelerates faster than management’s cautious language implies, ASP and instrument revenue could re-accelerate into late 2025, making current margin anxiety a setup for multiple expansion in 2026.

Key Decisions for Investors

• Long ISRG on a 6-12 month horizon into post-broad-launch rollout; use any 5-8% pullback on margin-guide headlines to build. Risk/reward skews favorable if procedure growth holds >13% and DV5 trade-ins ramp as a delayed catalyst.
• Sell near-dated upside via call spreads in ISRG if implied vol spikes around tariff/2025 margin commentary. The stock may trade sideways while accounting headwinds absorb the next 1-2 quarters.
• Pair trade: long ISRG / short SYK for 3-9 months. ISRG has the cleaner product-cycle catalyst and more visible recurring pull-through; SYK is more exposed to broader hospital capex sensitivity and less direct operating leverage to a platform refresh.
• Avoid chasing the stock immediately after any upbeat procedure print; wait for evidence that leasing and trade-ins are not depressing ASPs faster than procedure growth offsets. Better entry is after management confirms broad launch economics in mid-2025.